Cargando…
The progress of postapproval clinical studies on Sabin IPV
As one of the powerful vaccines for completely eradicating all types of poliovirus in the polio endgame period, the novel IPV, which is prepared from attenuated polio Sabin strains (sIPV) and is expected to reduce the overall biosafety risk, was licensed in Japan (sIPV-containing diphtheria-tetanus-...
Autores principales: | Shi, Li, Sun, Mingbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920192/ https://www.ncbi.nlm.nih.gov/pubmed/34213408 http://dx.doi.org/10.1080/21645515.2021.1940653 |
Ejemplares similares
-
Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries
por: George, Marina, et al.
Publicado: (2023) -
Mumps-specific antibody persistence in children aged 3–7 years immunized with two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China
por: Sun, Jinfang, et al.
Publicado: (2023) -
Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020)
por: Deng, Yan, et al.
Publicado: (2022) -
Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial
por: Sun, Dapeng, et al.
Publicado: (2023) -
An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox
por: Tomita, Noriko, et al.
Publicado: (2023)